Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function

References

• Steele K, Twenhafel N. Review paper: pathology of animal models of alphavirus encephalitis. Vet Pathol. 2010;47(5):790–16. doi:10.1177/0300985810372508.
   PubMed Web of Science ®Google Scholar
• Zacks M, Paessler S. Encephalitic alphaviruses. Vet Microbiol. 2010;140:281–86.
   PubMed Web of Science ®Google Scholar
• Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC. Venezuelan equine encephalitis. Annu Rev Entomol. 2004;49(1):141–74. doi:10.1146/annurev.ento.49.061802.123422.
   PubMedGoogle Scholar
• Jose J, Snyder JE, Kuhn RJ. A structural and functional perspective of alphavirus replication and assembly. Future Microbiol. 2009;4(7):837–56. doi:10.2217/fmb.09.59.
   PubMed Web of Science ®Google Scholar
• Kim AS, Kafai NM, Winkler ES, Gilliland TC Jr., Cottle EL, Earnest JT, Jethva PN, Kaplonek P, Shah AP, Fong RH, et al. Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope. Cell. 2021;184(17):4414–29.e19. doi:10.1016/j.cell.2021.07.006.
   PubMed Web of Science ®Google Scholar
• Leung JY, Ng MM, Chu JJ. Replication of alphaviruses: a review on the entry process of alphaviruses into cells. Adv Virol. 2011;2011:249640. doi:10.1155/2011/249640.
   PubMedGoogle Scholar
• Li L, Jose J, Xiang Y, Kuhn RJ, Rossmann MG. Structural changes of envelope proteins during alphavirus fusion. Nature. 2010;468(7324):705–8. doi:10.1038/nature09546.
   PubMed Web of Science ®Google Scholar
• Sanchez-San Martin C, Liu CY, Kielian M. Dealing with low pH: entry and exit of alphaviruses and flaviviruses. Trends Microbiol. 2009;17(11):514–21. doi:10.1016/j.tim.2009.08.002.
   PubMed Web of Science ®Google Scholar
• Williamson LE, Reeder KM, Bailey K, Tran MH, Roy V, Fouch ME, Kose N, Trivette A, Nargi RS, Winkler ES, et al. Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. Cell. 2021;184(17):4430–46.e22. doi:10.1016/j.cell.2021.07.033.
   PubMed Web of Science ®Google Scholar
• Rülker T, Voß L, Thullier P, LM OB, Pelat T, Perkins SD, Langermann C, Schirrmann T, Dübel S, Marschall H-J, et al. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS ONE. 2012;7(5):e37242. doi:10.1371/journal.pone.0037242.
   PubMed Web of Science ®Google Scholar
• Porta J, Jose J, Roehrig JT, Blair CD, Kuhn RJ, Rossmann MG, Dermody TS. Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies. J Virol. 2014;88(17):9616–23. doi:10.1128/JVI.01286-14.
   PubMed Web of Science ®Google Scholar
• Hunt AR, Frederickson S, Hinkel C, Bowdish KS, Roehrig JT. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J Gen Virol. 2006;87(Pt 9):2467–76. doi:10.1099/vir.0.81925-0.
   PubMedGoogle Scholar
• Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD, Weaver SC. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS neglected tropical diseases. PLoS Negl Trop Dis. 2010;4(7):e739. doi:10.1371/journal.pntd.0000739.
   PubMed Web of Science ®Google Scholar
• Kafai NM, Williamson LE, Binshtein E, Sukupolvi-Petty S, Gardner CL, Liu J, Mackin S, Kim AS, Kose N, Carnahan RH, et al. Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge. J Exp Med. 2022;219(4):e20212532. doi:10.1084/jem.20212532.
   PubMed Web of Science ®Google Scholar
• Goodchild S, O’Brien L, Steven J, Muller M, Lanning O, Logue C, D’Elia RV, Phillpotts RJ, Perkins SD. A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus. Antiviral Res. 2011;90(1):1–8. doi:10.1016/j.antiviral.2011.01.010.
   PubMed Web of Science ®Google Scholar
• Kim AS, Diamond MS. A molecular understanding of alphavirus entry and antibody protection. Nat Rev Microbiol. 2023;21(6):396–407. doi:10.1038/s41579-022-00825-7.
   PubMed Web of Science ®Google Scholar
• Hülseweh B, Rülker T, Pelat T, Langermann C, Frenzel A, Schirrmann T, Dübel S, Thullier P, Hust M. Human-like antibodies neutralizing Western equine encephalitis virus. MAbs. 2014;6(3):718–27. doi:10.4161/mabs.28170.
   PubMed Web of Science ®Google Scholar
• Burke CW, Froude JW, Miethe S, Hülseweh B, Hust M, Glass PJ. Human-like neutralizing antibodies protect mice from aerosol exposure with western equine encephalitis virus. Viruses. 2018;10(4):147. doi:10.3390/v10040147.
   PubMed Web of Science ®Google Scholar
• van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10(548):548. doi:10.3389/fimmu.2019.00548.
   PubMedGoogle Scholar
• Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2017;18(1):46. doi:10.1038/nri.2017.106.
   PubMed Web of Science ®Google Scholar
• Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, et al. Systematic analysis of monoclonal antibodies against ebola virus GP defines features that contribute to protection. Cell. 2018;174(4):938–52.e13. doi:10.1016/j.cell.2018.07.033.
   PubMed Web of Science ®Google Scholar
• Dias AG, Atyeo C, Loos C, Montoya M, Roy V, Bos S, Narvekar P, Singh T, Katzelnick LC, Kuan G, et al. Antibody fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. Sci Transl Med. 2022;14(651):eabm3151. doi:10.1126/scitranslmed.abm3151.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Ravetch JV. Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. Cancer Immunol Res. 2015;3(7):704. doi:10.1158/2326-6066.CIR-15-0120.
   PubMed Web of Science ®Google Scholar
• Earnest JT, Basore K, Roy V, Bailey AL, Wang D, Alter G, Fremont DH, Diamond MS. Neutralizing antibodies against mayaro virus require fc effector functions for protective activity. J Exp Med. 2019;216(10):2282–301. doi:10.1084/jem.20190736.
   PubMed Web of Science ®Google Scholar
• Earnest JT, Holmes AC, Basore K, Mack M, Fremont DH, Diamond MS. The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies. Cell Rep. 2021;35(1):108962. doi:10.1016/j.celrep.2021.108962.
   PubMed Web of Science ®Google Scholar
• Fox JM, Roy V, Gunn BM, Huang L, Edeling MA, Mack M, Fremont DH, Doranz BJ, Johnson S, Alter G, et al. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes. Sci Immunol. 2019;4(32):eaav5062. doi:10.1126/sciimmunol.aav5062.
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CMS, Landucci G, Forthal DN, Parren PWHI, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449(7158):101–4. doi:10.1038/nature06106.
   PubMed Web of Science ®Google Scholar
• Nasser R, Pelegrin M, Michaud HA, Plays M, Piechaczyk M, Gros L. Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol. 2010;84(19):10169–81. doi:10.1128/JVI.00568-10.
   PubMed Web of Science ®Google Scholar
• Zhang A, Stacey HD, D’Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat Rev Immunol. 2022;23(6):381–96. doi:10.1038/s41577-022-00813-1.
   PubMed Web of Science ®Google Scholar
• Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, Zost SJ, Jang H, Huang Y, Allen JD, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021;184(7):1804–20.e16. doi:10.1016/j.cell.2021.02.026.
   PubMed Web of Science ®Google Scholar
• Vanderven HA, Liu L, Ana-Sosa-Batiz F, Nguyen THO, Wan Y, Wines B, Hogarth PM, Tilmanis D, Reynaldi A, Parsons MS, et al. Fc functional antibodies in humans with severe H7N9 and seasonal influenza. JCI Insight. 2017;2(13). doi:10.1172/jci.insight.92750.
   PubMed Web of Science ®Google Scholar
• Keeler SP, Fox JM. Requirement of Fc-Fc gamma receptor interaction for antibody-based protection against emerging virus infections. Viruses [Internet]. 2021;13(6):1037. doi:10.3390/v13061037.
   PubMed Web of Science ®Google Scholar
• Fuller JP, Stavenhagen JB, Teeling JL. New roles for fc receptors in neurodegeneration-the impact on immunotherapy for Alzheimer’s disease. Front Neurosci. 2014;8:235. doi:10.3389/fnins.2014.00235.
   PubMed Web of Science ®Google Scholar
• Wang X, Mathieu M, Brezski RJ. IgG fc engineering to modulate antibody effector functions. Protein Cell. 2018;9(1):63–73. doi:10.1007/s13238-017-0473-8.
   PubMed Web of Science ®Google Scholar
• Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 fc. J Immunol. 2000;164(8):4178–84. doi:10.4049/jimmunol.164.8.4178.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520–. doi:10.3389/fimmu.2014.00520.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Ravetch JV. Fcγ receptor function and the design of vaccination strategies. Immunity. 2017;47(2):224–33. doi:10.1016/j.immuni.2017.07.009.
   PubMed Web of Science ®Google Scholar
• Lofano G, Gorman MJ, Yousif AS, Yu W-H, Fox JM, Dugast A-S, Ackerman ME, Suscovich TJ, Weiner J, Barouch D, et al. Antigen-specific antibody fc glycosylation enhances humoral immunity via the recruitment of complement. Sci Immunol. 2018;3(26):eaat7796. doi:10.1126/sciimmunol.aat7796.
   PubMed Web of Science ®Google Scholar
• Hunt AR, Bowen RA, Frederickson S, Maruyama T, Roehrig JT, Blair CD. Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection. Virology. 2011;414(2):146–52. doi:10.1016/j.virol.2011.03.016.
   PubMed Web of Science ®Google Scholar
• Cain MD, Salimi H, Gong Y, Yang L, Hamilton SL, Heffernan JR, Hou J, Miller MJ, Klein RS. Virus entry and replication in the brain precedes blood-brain barrier disruption during intranasal alphavirus infection. J Neuroimmunol. 2017;308:118–30. doi:10.1016/j.jneuroim.2017.04.008.
   PubMed Web of Science ®Google Scholar
• Julander JG, Skirpstunas R, Siddharthan V, Shafer K, Hoopes JD, Smee DF, Morrey JD. C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral Res. 2008;78(3):230–41. doi:10.1016/j.antiviral.2008.01.007.
   PubMed Web of Science ®Google Scholar
• Kinney RM, Chang GJ, Tsuchiya KR, Sneider JM, Roehrig JT, Woodward TM, Trent DW. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5’-noncoding region and the E2 envelope glycoprotein. J Virol. 1993;67(3):1269–77. doi:10.1128/jvi.67.3.1269-1277.1993.
   PubMed Web of Science ®Google Scholar
• Hezareh M, Hessell AJ, Jensen RC, van de Winkel JGJ, Parren PWHI. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus Type 1. J Virol. 2001;75(24):12161–68. doi:10.1128/JVI.75.24.12161-12168.2001.
   PubMed Web of Science ®Google Scholar
• Wilkinson I, Anderson S, Fry J, Julien LA, Neville D, Qureshi O, Watts G, Hale G. Fc-engineered antibodies with immune effector functions completely abolished. PLoS ONE. 2021;16(12):e0260954. doi:10.1371/journal.pone.0260954.
   PubMed Web of Science ®Google Scholar
• Xu D, Alegre M-L, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PWHI, Bluestone JA, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000;200(1):16–26. doi:10.1006/cimm.2000.1617.
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016;29(10):457–66. doi:10.1093/protein/gzw040.
   PubMed Web of Science ®Google Scholar
• Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes J-M, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJY, et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem. 2017;292(9):3900–8. doi:10.1074/jbc.M116.767749.
   PubMed Web of Science ®Google Scholar
• Karimi MA, Lee E, Bachmann MH, Salicioni AM, Behrens EM, Kambayashi T, Baldwin, CL. Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay. PLoS One [Internet]. 2014;9(2):e89357.
   PubMed Web of Science ®Google Scholar
• Uccellini MB, Aslam S, Liu STH, Alam F, García-Sastre A. Development of a macrophage-based ADCC assay. Vaccines (Basel). 2021;9(6):660. doi:10.3390/vaccines9060660.
   PubMed Web of Science ®Google Scholar
• Arduin E, Arora S, Bamert PR, Kuiper T, Popp S, Geisse S, Grau R, Calzascia T, Zenke G, Kovarik J, et al. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a. Mol Immunol. 2015;63(2):456–63. doi:10.1016/j.molimm.2014.09.017.
   PubMed Web of Science ®Google Scholar
• Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, Rispens T, Vidarsson G. Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs. 2017;9(5):767–73. doi:10.1080/19420862.2017.1323159.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JHW, Bleeker WK, Parren PWHI. Crosstalk between human IgG isotypes and murine effector cells. J Immunol. 2012;189(7):3430–38. doi:10.4049/jimmunol.1200356.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding. Sci. 2005;310(5753):1510–2. doi:10.1126/science.1118948.
   PubMed Web of Science ®Google Scholar
• Forrester MA, Wassall HJ, Hall LS, Cao H, Wilson HM, Barker RN, Vickers MA. Similarities and differences in surface receptor expression by THP-1 monocytes and differentiated macrophages polarized using seven different conditioning regimens. Cell Immunol. 2018;332:58–76. doi:10.1016/j.cellimm.2018.07.008.
   PubMed Web of Science ®Google Scholar
• Verma A, Ngundi MM, Meade BD, De Pascalis R, Elkins KL, Burns DL. Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays. Clin Vaccine Immunol. 2009;16(10):1405–12. doi:10.1128/CVI.00194-09.
   PubMedGoogle Scholar
• Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, et al. A role for fc function in therapeutic monoclonal antibody-mediated protection against ebola virus. Cell Host & Microbe. 2018;24(2):221–33.e5. doi:10.1016/j.chom.2018.07.009.
   PubMed Web of Science ®Google Scholar
• Bailey MJ, Duehr J, Dulin H, Broecker F, Brown JA, Arumemi FO, Bermúdez González MC, Leyva-Grado VH, Evans MJ, Simon V, et al. Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nat Commun. 2018;9(1):4560. doi:10.1038/s41467-018-07008-0.
   PubMedGoogle Scholar
• Chung KM, Nybakken GE, Thompson BS, Engle MJ, Marri A, Fremont DH, Diamond MS. Antibodies against west nile virus nonstructural protein NS1 prevent lethal infection through Fc γ receptor-dependent and -independent mechanisms. J Virol. 2006;80(3):1340–51. doi:10.1128/JVI.80.3.1340-1351.2006.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med. 2014;20(2):143–51. doi:10.1038/nm.3443.
   PubMed Web of Science ®Google Scholar
• Yu L, Liu X, Ye X, Su W, Zhang X, Deng W, Luo J, Xiang M, Guo W, Zhang S, et al. Monoclonal antibodies against zika virus NS1 protein confer protection via Fcγ receptor-dependent and -independent pathways. mBio. 2021;12(1):10–128. doi:10.1128/mBio.03179-20.
   Web of Science ®Google Scholar
• Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MKS, et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog. 2013;9(4):e1003312. doi:10.1371/journal.ppat.1003312.
   PubMed Web of Science ®Google Scholar
• Zhou QF, Fox JM, Earnest JT, Ng T-S, Kim AS, Fibriansah G, Kostyuchenko VA, Shi J, Shu B, Diamond MS, et al. Structural basis of Chikungunya virus inhibition by monoclonal antibodies. Proc Natl Acad Sci USA. 2020;117(44):27637–45. doi:10.1073/pnas.2008051117.
   PubMed Web of Science ®Google Scholar
• Powell LA, Miller A, Fox JM, Kose N, Klose T, Kim AS, Bombardi R, Tennekoon RN, Dharshan de Silva A, Carnahan RH, et al. Human mAbs broadly protect against arthritogenic alphaviruses by recognizing conserved elements of the Mxra8 receptor-binding site. Cell Host & Microbe. 2020;28(5):699–711. e7. doi:10.1016/j.chom.2020.07.008.
   PubMed Web of Science ®Google Scholar
• Fox JM, Huang L, Tahan S, Powell LA, Crowe JE Jr., Wang D, Diamond MS. A cross-reactive antibody protects against Ross River virus musculoskeletal disease despite rapid neutralization escape in mice. PLoS Pathog. 2020;16(8):e1008743. doi:10.1371/journal.ppat.1008743.
   PubMed Web of Science ®Google Scholar
• Parekh BS, Berger E, Sibley S, Cahya S, Xiao L, LaCerte MA, Vaillancourt P, Wooden S, Gately D. Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs. 2012;4(3):310–18. doi:10.4161/mabs.19873.
   PubMed Web of Science ®Google Scholar
• Brooke CB, Schäfer A, Matsushima GK, White LJ, Johnston RE. Early activation of the host complement system is required to restrict central nervous system invasion and limit neuropathology during Venezuelan equine encephalitis virus infection. J Gen Virol. 2012;93(Pt 4):797–806. doi:10.1099/vir.0.038281-0.
   PubMedGoogle Scholar
• Sharma A, Knollmann-Ritschel B. Current understanding of the molecular basis of venezuelan equine encephalitis virus pathogenesis and vaccine development. Viruses. 2019;11(2):164. doi:10.3390/v11020164.
   PubMed Web of Science ®Google Scholar
• Li L, Jose J, Xiang Y, Kuhn RJ, Rossman MG. Structural changes of envelope proteins during alphavirus fusion. Nature. 2010;468(7324):705–8. doi:10.1038/nature09546.
   PubMed Web of Science ®Google Scholar